ArticleAdvanced materials (Deerfield Beach, Fla.)2018
Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides.
Article in Advanced materials (Deerfield Beach, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Nanotechnology-donated ischemic stroke therapeutics: evolving strategies from the basic to the cutting-edge.Theranostics · 2026Review
- Stimulus-responsive smart bioactive glass composites for repair of complex tissue defects.Theranostics · 2025Review
- Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.Bioactive materials · 2025Review
- Neuroprotective Effects of Melittin Against Cerebral Ischemia and Inflammatory Injury via Upregulation of MCPIP1 to Suppress NF-κB Activation In Vivo and In Vitro.Neurochemical research · 2024Article
- Iron-Gallic Acid Peptide Nanoparticles as a Versatile Platform for Cellular Delivery with Synergistic ROS Enhancement Effect.Pharmaceutics · 2023Article
- Nanoparticle-based drug delivery for the treatment of traumatic brain injury.Expert opinion on drug delivery · 2023Review
- Article
- Recent advancements in enzyme-incorporated nanomaterials: Synthesis, mechanistic formation, and applications.Biotechnology and bioengineering · 2022Review
- Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery.Bioactive materials · 2022Article
- Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- A manganese (II)-based coordinative dendrimer with robust efficiency in intracellular peptide delivery.Bioactive materials · 2022Article
- Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.Frontiers in pharmacology · 2022Review
- Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy.Pharmaceutics · 2021Review
- Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.Acta pharmaceutica Sinica. B · 2021Review
- Fluoroalkylation promotes cytosolic peptide delivery.Science advances · 2020Article
- Autocatalytic Delivery of Brain Tumor-targeting, Size-shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases.Advanced functional materials · 2020Article
- Targeted Delivery of Secretory Promelittin via Novel Poly(lactone-Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery.Frontiers in chemistry · 2020Review
- Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles.Theranostics · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors.
Funding
Abstract
Clinical translation of therapeutic peptides, particularly those that require penetration of the cell membrane or are cytolytic, is a major challenge. A novel approach based on a complementary mechanism, which has been widely used for guided synthesis of DNA or RNA nanoparticles, for de novo design of activatable protein nanoparticles (APNPs) for targeted delivery of therapeutic peptides is described. APNPs are formed through self-assembly of three independent polypeptides based on pairwise coiled-coil dimerization. They are capable of long circulation in the blood and can be engineered to target diseases. Peptides to be delivered are incorporated into APNPs and released into the disease microenvironment by locally enriched proteases. It is demonstrated that APNPs mediate efficient delivery of NR2B9c, a neuroprotective peptide that functions after cell penetration, and melittin, a cytolytic peptide that perturbs the lipid bilayer, for effective treatment of stroke and cancer, respectively. Due to their robust properties, simple design, and economic costs, APNPs have great potential to serve as a versatile platform for controlled delivery of therapeutic peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.